Resources
About Us
Home Report
Store
Recombinant Coagulation Factors Market
Recombinant Coagulation Factors Market Size, Share, Forecast, & Trends Analysis by Type (Factor VIII, Factor IX), Source (CHO, HEK), Application (Hemophilia (Type A, Type B), Others), End User (Hospitals, CRO) - Global Forecast to 2031
Report ID:MRHC - 104168 Pages: 180 Jul-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 HoursRecombinant Coagulation Factors Market Size & Forecast
The Recombinant Coagulation Factors Market is projected to reach $26.29 billion by 2031, at a CAGR of 8.6% from 2024 to 2031. Recombinant coagulation factors differ from plasma-derived factors as they are produced using recombinant DNA technology. This production method ensures a very low risk of blood-borne transmission of infectious diseases, effectively eliminating the threat of viruses such as hepatitis C and human immunodeficiency virus (HIV). As a result, recombinant coagulation factors are primarily used in treating bleeding disorders such as hemophilia.
The increasing prevalence of hemophilia and other bleeding disorders, growing R&D for coagulation factors, growing awareness about the benefits of the recombinant coagulation factors, and increasing prophylactic treatment for hemophilia across the globe are driving the growth of the recombinant coagulation factors market. However, the high cost of recombinant factors compared to plasma-derived factors and the limited accessibility & availability of recombinant clotting factors in developing & underdeveloped countries are expected to restrain the growth of this market.
Furthermore, untapped markets in emerging economies and rising healthcare expenditure are expected to create market growth opportunities. However, challenges in the production of recombinant coagulation factors, stringent regulatory requirements, lack of reimbursement in some countries, and lack of awareness among patients are some of the challenges impacting the market’s growth.
Recombinant Coagulation Factors Market Growth Drivers
Rising Prevalence of Hemophilia
Hemophilia A and B are the most common severe hereditary hemorrhagic disorders. These disorders are caused due to coagulation factor VIII and factor IX protein deficiency. Patients with these disorders have prolonged bleeding with or without trauma, depending on the factor activity. According to National Center for Biotechnology Information (NCBI) data, in September 2022, the estimated frequency of hemophilia was about 1 in 10,000 live births, and the number of people worldwide living with hemophilia was about 4,00,000. Hemophilia A is more prevalent, about 80-85% of the total hemophilia population. Hemophilia A is present in 1 in 5,000 live male births, whereas hemophilia B is present in 1 in 30,000 live male births.
In order to tackle this disorder, coagulation factors, also known as clotting factors, are gaining popularity. The wide availability of recombinant factor VIII, viral inactivation, and better screening technology make the product and treatment safer. Thus, despite the availability of plasma-derived factor concentrates, about 75% of patients with hemophilia worldwide receive recombinant factor VIII products since they are much safer. Thus, the effectiveness of recombinant clotting factors products supports better treatment for hemophilic patients, driving the growth of this market.
Click here to: Get Free Sample Pages of this Report
Availability of Reimbursement Policies for Hemophilia
Hemophilia, a treatable yet costly rare disease, receives reimbursement coverage in some countries such as China, the U.S., and European countries. The availability of reimbursement policies for the disease increases the accessibility to recombinant coagulation factors. From 2012, the Chinese Ministry of Health has prioritized 20 high-cost diseases (including hemophilia) to ease patients’ economic burden. Similarly, from 2021 onwards, the Medicaid and NC Health Choice programs in the U.S. began covering [coagulation factor VIIa (recombinant)-jncw] lyophilized powder for solution, for intravenous use (Sevenfact) for use in the Physician Administered Drug Program.
Recombinant Coagulation Factors Market Trends
Extended Half-life of the Factors
The half-life of the recombinant coagulation factors is referred to as the time taken by the factor to reduce the level by half. Many key players are trying to increase the half-life of recombinant coagulation factors to improve the effectiveness of treatment against Hemophilia. Extended half-life recombinant products are produced to improve the pharmacokinetic profile of factors to enable better hemostatic protection with a fewer number of injections in persons with hemophilia.
Pharmaceutical companies such as Novo Nordisk (Denmark), Baxter International Inc. (U.S.), and Bayer AG (Germany) are using the PEGylation method to extend the half-life of recombinant coagulation factors. The extended half-life of recombinant factors helps in reducing the number of injections, improving treatment adherence, enhancing protection against bleeding, and ultimately reducing economic burden.
Recombinant Coagulation Factors Market Opportunity
Preference for Recombinant Coagulation Factors over Plasma-derived Factors
Plasma-derived concentrates are made from human blood donated by healthy volunteers and screened for safety. Recombinant factor products are made in a laboratory using recombinant technology. These products are not made from human blood. Since recombinant factor products are manufactured in the laboratory, it avoids the risk of transmission of blood-borne viruses.
In the past, patients with bleeding disorders such as hemophilia relied on plasma concentrates for treatment. However, those treated with plasma concentrates derived from pooled plasma faced a significantly high risk of HIV infection due to the lack of effective screening for HIV in plasma and plasma donors. Historically, about 70-75% of patients with severe hemophilia were found to have contracted HIV as a result. This scenario prompted the development of recombinant coagulation factors, which provide a safer alternative to plasma-derived products by eliminating the risk of blood-borne transmission of infectious diseases. Therefore, the preference for recombinant factors over plasma-derived factors is expected to create growth opportunities for stakeholders in this market.
Recombinant Coagulation Factors Market Analysis: Key Findings
By Type: In 2024, the Recombinant Factor VIII Segment to Dominate the Recombinant Coagulation Factors Market
Based on type, the recombinant coagulation factors market is segmented into recombinant factor VIII, recombinant factor IX, and other types. In 2024, the recombinant factor VIII segment is expected to account for the largest share of 59.5% of this market. The large market share of this segment is attributed to advancements in recombinant technology, high demand for recombinant factor VIII due to a large patient pool of individuals with Hemophilia A, rising accessibility of treatment, and growing awareness about the benefits of recombinant coagulation factors. Factor VIII plays a crucial role in mitigating chronic damage and preventing fatal bleeding, making it a preferred treatment for bleeding disorders. These benefits contribute to the large market share of this segment.
By Application: In 2024, the Hemophilia A Segment to Dominate the Recombinant Coagulation Factors Market
Based on application, the recombinant coagulation factors market is segmented into hemophilia A, hemophilia B, and other applications. In 2024, the hemophilia A segment is expected to account for the largest share of 64.3% of the recombinant coagulation factors market. This segment’s large market share can be attributed to the larger number of patients with hemophilia A compared to hemophilia B, the increasing global prevalence of hemophilia, and supportive government initiatives aimed at enhancing treatment for hemophilia A. For instance, under India's National Health Mission, the government provides financial aid for the treatment of hemophilia A. Similarly, in the U.S., the National Hemophilia Program tracks patient data at national and regional levels to assess outcomes and improve care for individuals with hemophilia A.
By End User: In 2024, the Hospitals & Clinics Segment to Dominate the Recombinant Coagulation Factors Market
Based on end user, the recombinant coagulation factors market is segmented into hospitals & clinics and clinical research laboratories. In 2024, the hospitals & clinics segment is expected to account for the largest share of the recombinant coagulation factors market. The large market share of this segment is attributed to the increased adoption of recombinant coagulation factors in hospitals for the treatment of coagulation disorders, rising healthcare expenditure, and rising awareness among healthcare professionals. Furthermore, patients have access to reimbursement policies and government schemes designed to support the treatment of bleeding disorders. Many hospitals and clinics are forming partnerships with key players or other healthcare facilities to enhance treatment accessibility. For instance, in May 2023, the Amrita Hemophilia Treatment Center (India) partnered with the Manchester Hemophilia Treatment Center (U.S.) through a twinning program aimed at improving hemophilia care in India.
Geographical Analysis
North America to Dominate the Market
In 2024, North America is expected to account for the largest share of the 43.4% of recombinant coagulation factors market. North America’s significant market share can be attributed to the increasing prevalence of hemophilia and bleeding disorders, rising accessibility and affordability for the treatment, supportive government initiatives aimed at enhancing treatment, the proliferation of treatment & research centers for hemophilia, and the increasing number of awareness programs for hemophilia. According to the Centers for Disease Control and Prevention, the hemophilia program is the largest in the CDC’s Division of Blood Disorders, working towards creating awareness about hemophilia causes, symptoms, and treatment.
However, the market in Asia-Pacific is projected to register the highest CAGR of 10.3% during the forecast period. The growth of this market is driven by the increasing healthcare investments in developing countries like China and India and the rising preference for recombinant technology due to its advantages over traditional methods.
Recombinant Coagulation Factors Market: Key Companies
The report offers a competitive landscape based on an extensive assessment of the leading players’ product offerings and geographic presence and the key growth strategies adopted by them over the past few years. The key players profiled in the recombinant coagulation factors market report are Baxter International Inc. (U.S.), Grifols, S.A. (Spain), CSL Limited (Australia), Octapharma AG (Switzerland), Novo Nordisk A/S (Denmark), Biogen Inc. (U.S.), Bayer AG (Germany), Kedrion S.p.A. (Italy), Emergent BioSolutions (U.S.), and Pfizer Inc. (U.S.).
Recombinant Coagulation Factors Market Overview: Latest Developments from Key Industry Players
- In April 2024, Pfizer Inc. (U.S.) received approval for BEQVEZ (fidanacogene elaparvovec-dzkt) from the U.S. FDA for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX).
- In August 2023, Novo Nordisk (Denmark) received approval for Alhemo (concizumab injection) from Health Canada for the treatment of hemophilia A patients over the age of 12 years or older who test positive for factor VIII inhibitors.
- In February 2023, Sanofi S.A. (France) received approval from the U.S. FDA for ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]. The approved factor is a new class of factor VIII therapy for hemophilia A.
Recombinant Coagulation Factors Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
180 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2022 |
|
CAGR |
8.6% |
|
Estimated Market Size (Value) |
$26.29 billion by 2031 |
|
Segments Covered |
By Type
By Source
By Application
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Netherlands, Sweden, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa |
|
Key Companies |
Baxter International Inc. (U.S.), Grifols, S.A. (Spain), CSL Limited (Australia), Octapharma AG (Switzerland), Novo Nordisk A/S (Denmark), Biogen Inc. (U.S.), Bayer AG (Germany), Kedrion S.p.A. (Italy), Emergent BioSolutions (U.S.), and Pfizer Inc. (U.S.). |
Key questions answered in the recombinant coagulation factors market report:
This study offers a detailed assessment of the recombinant coagulation factors market and analyzes the market sizes & forecasts based on type, source, application, and end user. This report also involves the value analysis of various segments and subsegments of the recombinant coagulation factors market at the regional and country levels.
The recombinant coagulation factors market is projected to reach $26.29 billion by 2031, at a CAGR of 8.6% during the forecast period.
Based on type, in 2024, the recombinant factor VIII segment is expected to account for the largest share of the market due to increased demand for the treatment of hemophilia A and advancement in recombinant technology.
Based on application, the hemophilia A segment is projected to register the highest CAGR during the forecast period. The growth of this segment is driven by the increasing incidence of hemophilia and the rise in diagnosis rates, leading to the increased adoption of recombinant coagulation factors.
The increasing prevalence of hemophilia and other bleeding disorders, growing R&D for coagulation factors, growing awareness about the benefits of the recombinant coagulation factors, and increasing prophylactic treatment for hemophilia across the globe are driving the growth of the recombinant coagulation factors market. Furthermore, untapped markets in emerging economies and rising healthcare expenditure are expected to create market growth opportunities.
The key players profiled in the recombinant coagulation factors market study are Baxter International Inc. (U.S.), Grifols, S.A. (Spain), CSL Limited (Australia), Octapharma AG (Switzerland), Novo Nordisk A/S (Denmark), Biogen Inc. (U.S.), Bayer AG (Germany), Kedrion S.p.A. (Italy), Emergent BioSolutions (U.S.), and Pfizer Inc. (U.S.).
Emerging economies such as China and India are projected to offer significant growth opportunities to the market players due to rising healthcare expenditure, large patient volume suffering from hemophilia, and the high market expansion potential in these countries.
1. Market Scope & Definition
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for this Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Hemophilia and Other Bleeding Disorders
4.2.2. Growing R&D for Coagulation Factors
4.2.3. Growing Awareness About the Benefits of Recombinant Coagulation Factors
4.2.4. Increasing Prophylactic Treatment for Hemophilia
4.3. Restraints
4.3.1. High Cost of Recombinant Factors Compared to Plasma-derived Products
4.3.2. Limited Accessibility and Availability of Recombinant Clotting Factors in Developing & Underdeveloped Countries
4.4. Opportunities
4.4.1. Potential Emerging Economies
4.4.2. Rising Healthcare Expenditure
4.5. Challenge
4.5.1. Manufacturing Challenges in the Production of Recombinant Coagulation Factors
4.5.2. Stringent Regulatory Requirements
4.5.3. Lack of Reimbursement in Some Countries
4.5.4. Lack of Awareness Among Patients
4.6. Pricing Analysis
4.7. Recombinant Coagulation Factors Pipeline Analysis
4.8. Regulatory Analysis
4.9. Industry & Technology Trends
5. Recombinant Coagulation Factors Market Assessment—by Type
5.1. Overview
5.2. Recombinant Factor VIII
5.3. Recombinant Factor IX
5.4. Other Types
6. Recombinant Coagulation Factors Market Assessment—by Source
6.1. Introduction
6.2. Chinese Hamster Ovary (CHO) Cell Line
6.3. Human Embryonic Kidney (HEK) Cell Line
6.4. Other Sources
7. Recombinant Coagulation Factors Market Assessment—by Application
7.1. Introduction
7.2. Hemophilia A
7.3. Hemophilia B
7.4. Other Applications
8. Recombinant Coagulation Factors Market Assessment—by End User
8.1. Introduction
8.2. Hospitals & Clinics
8.3. Clinical Research Laboratories
9. Recombinant Coagulation Factors Market Assessment—by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Netherlands
9.3.7. Sweden
9.3.8. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. India
9.4.3. Japan
9.4.4. Australia
9.4.5. Rest of Asia-Pacific
9.5. Latin America
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Vendor Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis (2023)
11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
11.1. Baxter International Inc.
11.2. Grifols, S.A.
11.3. CSL Limited
11.4. Octapharma AG
11.5. Kedrion S.p.A.
11.6. Pfizer Inc.
11.7. Novo Nordisk A/S
11.8. Bayer AG
11.9. Biogen, Inc.
11.10. Emergent BioSolutions
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Global Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 2 Global Recombinant Factor VIII Market, by Country/Region, 2022–2031 (USD Million)
Table 3 Vendors Offering Recombinant Factor VIII
Table 4 Global Recombinant Factor IX Market, by Country/Region, 2022–2031 (USD Million)
Table 5 Vendors Offering Recombinant Factor IX
Table 6 Global Other Recombinant Factor Types Market, by Country/Region, 2022–2031 (USD Million)
Table 7 Global Recombinant Coagulation Factors Market, by Source, 2022–2031 (USD Million)
Table 8 Global Chinese Hamster Ovary (CHO) Cell Line Market, by Type, 2022–2031 (USD Million)
Table 9 Global Human Embryonic Kidney (HEK) Cell Line Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Other Sources Market, by Country/Region, 2022–2031 (USD Million)
Table 11 Global Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 12 Global Hemophilia A Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Global Hemophilia B Market, by Country/Region, 2022–2031 (USD Million)
Table 14 Global Other Applications Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 16 Global Recombinant Coagulation Factors Market for Hospitals & Clinics, by Type, 2022–2031 (USD Million)
Table 17 Global Recombinant Coagulation Factors Market for Clinical Research Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 18 Global Recombinant Coagulation Factors Market, by Country/Region, 2022–2031 (USD Million)
Table 19 North America: Recombinant Coagulation Factors Market, by Country, 2022–2031 (USD Million)
Table 20 North America: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 21 North America: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 22 North America: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 23 North America: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 24 U.S.: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 25 U.S.: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 26 U.S.: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 27 U.S.: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 28 Canada: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 29 Canada: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 30 Canada: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 31 Canada: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 32 Europe: Recombinant Coagulation Factors Market, by Country/Region, 2022–2031 (USD Million)
Table 33 Europe: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 34 Europe: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 35 Europe: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 36 Europe: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 37 Germany: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 38 Germany: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 39 Germany: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 40 Germany: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 41 France: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 42 France: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 43 France: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 44 France: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 45 U.K.: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 46 U.K.: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 47 U.K.: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 48 U.K.: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 49 Italy: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 50 Italy: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 51 Italy: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 52 Italy: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 53 Spain: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 54 Spain: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 55 Spain: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 56 Spain: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 57 Netherlands: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 58 Netherlands: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 59 Netherlands: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 60 Netherlands: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 61 Sweden: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 62 Sweden: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 63 Sweden: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 64 Sweden: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 65 Rest of Europe: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 66 Rest of Europe: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 67 Rest of Europe: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 68 Rest of Europe: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 69 Asia-Pacific: Recombinant Coagulation Factors Market, by Country/Region, 2022–2031 (USD Million)
Table 70 Asia-Pacific: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 71 Asia-Pacific: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 72 Asia-Pacific: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 73 Asia-Pacific: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 74 China: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 75 China: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 76 China: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 77 China: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 78 India: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 79 India: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 80 India: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 81 India: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 82 Japan: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 83 Japan: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 84 Japan: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 85 Japan: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 86 Australia: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 87 Australia: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 88 Australia: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 89 Australia: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 90 Rest of Asia-Pacific: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 91 Rest of Asia-Pacific: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 92 Rest of Asia-Pacific: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 93 Rest of Asia-Pacific: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 94 Latin America: Recombinant Coagulation Factors Market, by Country/Region, 2022–2031 (USD Million)
Table 95 Latin America: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 96 Latin America: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 97 Latin America: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 98 Latin America: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 99 Brazil: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 100 Brazil: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 101 Brazil: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 102 Brazil: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 103 Mexico: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 104 Mexico: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 105 Mexico: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 106 Mexico: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 107 Rest of Latin America: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 108 Rest of Latin America: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 109 Rest of Latin America: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 110 Rest of Latin America: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 111 Middle East & Africa: Recombinant Coagulation Factors Market, by Type, 2022–2031 (USD Million)
Table 112 Middle East & Africa: Recombinant Coagulation Factors Market, by Source 2022–2031 (USD Million)
Table 113 Middle East & Africa: Recombinant Coagulation Factors Market, by Application, 2022–2031 (USD Million)
Table 114 Middle East & Africa: Recombinant Coagulation Factors Market, by End User, 2022–2031 (USD Million)
Table 115 Recent Developments, by Company, 2021–2024
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Estimation
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Market Sizing and Growth Forecast Approach
Figure 6 Global Recombinant Coagulation Factors Market, by Type, 2024 Vs. 2031 (USD Million)
Figure 7 Global Recombinant Coagulation Factors Market, by Source, 2024 Vs. 2031 (USD Million)
Figure 8 Global Recombinant Coagulation Factors Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 9 Global Recombinant Coagulation Factors Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 10 Global Recombinant Coagulation Factors Market, by Geography
Figure 11 Global Recombinant Coagulation Factors Market: Impact Analysis of Market Dynamics (2023–2030)
Figure 12 Global Recombinant Coagulation Factors Market, by Type, 2024 Vs. 2031 (USD Million)
Figure 13 Global Recombinant Coagulation Factors Market, by Source, 2024 Vs. 2031 (USD Million)
Figure 14 Global Recombinant Coagulation Factors Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 15 Global Recombinant Coagulation Factors Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 16 Global Recombinant Coagulation Factors Market, by Geography, 2024 Vs. 2031 (USD Million)
Figure 17 North America: Recombinant Coagulation Factors Market Snapshot
Figure 18 Asia-Pacific: Recombinant Coagulation Factors Market Snapshot
Figure 19 Europe: Recombinant Coagulation Factors Market Snapshot
Figure 20 Latin America: Recombinant Coagulation Factors Market Snapshot
Figure 21 Key Growth Strategies Adopted by Leading Players, 2021–2024
Figure 22 Recombinant Coagulation Factors: Competitive Benchmarking, by Type
Figure 23 Recombinant Coagulation Factors: Competitive Benchmarking, by Geography
Figure 24 Market Share Analysis: Recombinant Coagulation Factors Industry, 2023
Figure 25 Baxter International Inc.: Financial Overview (2023)
Figure 26 Grifols, S.A.: Financial Overview (2023)
Figure 27 CSL Limited: Financial Overview (2023)
Figure 28 Octapharma AG: Financial Overview (2023)
Figure 29 Kedrion S.p.A.: Financial Overview (2023)
Figure 30 Pfizer Inc.: Financial Overview (2023)
Figure 31 Novo Nordisk A/S: Financial Overview (2023)
Figure 32 Bayer AG: Financial Overview (2023)
Figure 33 Biogen Inc.: Financial Overview (2023)
Figure 34 Emergent BioSolutions: Financial Overview (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Latin America PoC Diagnostics Market - Opportunity Analysis and Industry Forecast (2020-2027)
Published Date: Jul-2020
Cell Culture Reagents Market - Global Opportunity Analysis and Industry Forecast (2022-2029)
Published Date: Jul-2022
Indonesia IVD Market - Opportunity Analysis And Industry Forecast (2022-2029)
Published Date: Sep-2022
Nepal IVD Market - Opportunity Analysis And Industry Forecast (2022-2029)
Published Date: Sep-2022
Africa IVD Market - Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jul-2024
